VCM
ADCT icon

Voleon Capital Management’s ADC Therapeutics ADCT Stock Holding History

Voleon Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-513,831
Closed -$1.93M – 764
2026
Q1 		$1.93M Buy
513,831
+49,672
+11% +$196K 0.04% 338
2025
Q4 		$1.64M Buy
464,159
+393,848
+560% +$1.6M 0.04% 365
2025
Q3 		$281K Buy
+70,311
New +$222K 0.01% 738

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Voleon Capital Management's ADCT Position: Q2 2026 in Review

Voleon Capital Management sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 513,831 shares — an estimated $1.93M sold.

Voleon Capital Management first reported a position in ADCT in Q3 2025 and held it in 3 quarters. The position peaked at $1.93M in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Voleon Capital Management reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Voleon Capital Management sold 513,831 ADC Therapeutics shares in Q2 2026, an estimated $1.93M.
  • Voleon Capital Management first reported a position in ADC Therapeutics in Q3 2025 and held it in 3 quarters.
  • Voleon Capital Management's ADC Therapeutics position peaked at $1.93M in Q1 2026.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.